Excelsior Biopharma

Excelsior Biopharma is a clinical-stage biotechnology company focused on the development of high-quality biosimilars and biobetters for global markets. Headquartered in Taiwan with research facilities in the United States, the company specializes in monoclonal antibody therapeutics for immunology and oncology. Its lead candidate, EBI-001, is a biosimilar of tocilizumab targeting the interleukin-6 receptor for the treatment of rheumatoid arthritis and other inflammatory diseases. The company is also advancing EBI-005, a bevacizumab biosimilar aimed at various solid tumors including colorectal cancer. Excelsior Biopharma leverages advanced protein engineering and cell line development platforms to improve manufacturing efficiency and drug efficacy. By focusing on established therapeutic targets, the company aims to provide more accessible and affordable treatment options for patients worldwide.